Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miransertib - Merck & Co

Next Previous
X
Search
Drug Profile

Miransertib - Merck & Co

Alternative Names: ARQ 092; MK 7075

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ArQule; Daiichi Sankyo Company
  • Developer ArQule; Merck & Co; Merck Sharp & Dohme Corp.; National Human Genome Research Institute
  • Class Antineoplastics; Cardiovascular therapies; Cyclobutanes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Proteus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Growth disorders; Proteus syndrome
  • Discontinued Congenital heart defects; Endometrial cancer; Lymphoma; Ovarian cancer; Solid tumours; Vaso-occlusive crisis

Most Recent Events

  • 08 Mar 2023 Discontinued - Phase-I for Endometrial cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 08 Mar 2023 Discontinued - Phase-I for Lymphoma (Monotherapy, Second-line therapy or greater) in USA (PO)
  • 08 Mar 2023 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top